PODD Stock Summary and Trading Ideas (Insulet | NASDAQ:PODD)

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Insulet trades on the NASDAQ stock market under the symbol PODD.

As of December 8, 2025, PODD stock price declined to $296.19 with 578,307 million shares trading.

PODD has a beta of 0.51, meaning it tends to be less sensitive to market movements. PODD has a correlation of 0.09 to the broad based SPY ETF.

PODD has a market cap of $20.84 billion. This is considered a Large Cap stock.

Last quarter Insulet reported $706 million in Revenue and $1.24 earnings per share. This beat revenue expectation by $28 million and exceeded earnings estimates by $.10.

In the last 3 years, PODD traded as high as $354.88 and as low as $125.82.

The top ETF exchange traded funds that PODD belongs to (by Net Assets): VTI, VOO, IVV, VB, SPY.

PODD has underperformed the market in the last year with a price return of +10.7% while the SPY ETF gained +13.9%. PODD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.0% and -10.6%, respectively, while the SPY returned +5.9% and +3.7%, respectively.

PODD support price is $296.80 and resistance is $312.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PODD shares will trade within this expected range on the day.